Ian Tannock on the Global view of Advanced Prostate Cancer
March 14, 2017
Ian Tannock is Emeritus Professor of Medicine and Medical Biophysics at Princess Margaret Cancer Centre and University of Toronto. He obtained his PhD in London, England and his MD at University of Pennsylvania, Philadelphia, USA. His clinical research investigates methods related to cancer clinical trials, and he chaired trials for men with metastatic prostate cancer that led to licensing of previous (mitoxantrone) and current (docetaxel) standard chemotherapy.
Charles Ryan, MD
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage
Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer